This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Chelsea Therapeutics International's CEO Discusses Q4 2011 Results - Earnings Call Transcript

Chelsea Therapeutics International, Ltd. ( CHTP)

Q4 2011 Earnings Call

March 6, 2012 4:30 pm ET


Kate McNeil - Director, IR

Simon Pedder - President and CEO

Nick Riehle - CFO

Art Hewitt - CSO

Bill Schwieterman - CMO

Keith Schmidt - VP, Marketing and Sales


Robyn Karnauskas - Deutsche Bank

Liana Moussatos - Wedbush Securities

Alan Carr - Needham & Company

Jonathan Eckard - Leerink Swann

Juan Sanchez - Ladenburg



Good day, and welcome to the Chelsea Therapeutics International fourth quarter conference call. (Operator Instructions) I would now like to introduce the host for today's conference, Ms. Kate McNeil, Director of Investor Relations.

Kate McNeil

Good afternoon and welcome to Chelsea Therapeutics fourth quarter and full year 2011 conference call. We announced our fourth quarter full year 2011 results this afternoon after the close of the U.S. financial markets and our press release can be found on our website at

Joining me from Chelsea Therapeutics is Dr. Simon Pedder, President and Chief Executive Officer; Mr. Nick Riehle, Chief Financial Officer; Dr. Art Hewitt, Chief Scientific Officer; Dr. Bill Schwieterman, Chief Medical Officer; and Mr. Keith Schmidt, Vice President of Marketing and Sales.

Before I turn the meeting over to Dr. Pedder, let me note that some of the remarks you'll hear today may contain forward-looking statements about the company's performance. Actual future results might differ materially from those projected in these forward-looking statements.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.02 0.00%
FB $104.07 0.00%
GOOG $683.57 0.00%
TSLA $162.60 0.00%
YHOO $27.97 0.00%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs